Peficitinib, a investigational drug targeting SYK , represents a significant breakthrough in the management of inflammatory joint conditions. Initial patient trials suggest that it appears to https://peficitinib302156.pointblog.net/peficitinib-a-potential-hope-for-ra-joint-disease-96048284